NASDAQ:GNOM Global X Genomics & Biotechnology ETF (GNOM) Price, Holdings, & News $63.34 +1.13 (+1.81%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOptions ChainOwnershipRatings About Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GNOM alerts:Sign Up Key Stats Today's Range$62.22▼$62.6650-Day Range$53.57▼$67.8552-Week Range$36.13▼$68.00Volume3,867 shsAverage Volume17,945 shsMarket Capitalization$126.63 millionAssets Under Management$93.74 millionDividend YieldN/ANet Expense Ratio0.50%Aggregate RatingModerate Buy ETF Overview Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company. Read More Global X Genomics & Biotechnology ETF ExpensesTypeGNOMTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.50%0.57%0.57%0.54%0.53%Other Expenses0.00%0.57%0.53%0.38%0.54%Total Expense0.50%0.72%0.75%0.69%0.73%Fee Waiver0.00%-0.72%-0.67%-0.41%-0.68%Net Expense0.50%0.60%0.63%0.61%0.60% Receive GNOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNOM ETF News HeadlinesGlobal X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?September 5, 2026 | americanbankingnews.comGNOM: Dividendenhistorie, Rendite und Ex-Dividenden-TagAugust 22, 2026 | de.investing.comHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.September 14 at 1:00 AM | Base Camp Trading (Ad)(GNOM) Global X Genomics & Biotechnology ETFAugust 21, 2026 | sa.investing.comGlobal X Genomics & Biotechnology UCITS ETF USD AccAugust 18, 2026 | markets.ft.comGlobal X Genomics & Biotechnology ETFJuly 31, 2026 | markets.businessinsider.comSee More Headlines GNOM ETF - Frequently Asked Questions How have GNOM shares performed this year? Global X Genomics & Biotechnology ETF's stock was trading at $45.46 on January 1st, 2026. Since then, GNOM shares have increased by 38.1% and is now trading at $62.7740. When did Global X Genomics & Biotechnology ETF's stock split? Global X Genomics & Biotechnology ETF shares reverse split on the morning of Tuesday, September 2nd 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. Who are Global X Genomics & Biotechnology ETF's major shareholders? Top institutional investors of Global X Genomics & Biotechnology ETF include C M Bidwell & Associates Ltd. (0.15%). How do I buy shares of Global X Genomics & Biotechnology ETF? Shares of GNOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Global X Genomics & Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Global X Genomics & Biotechnology ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Teladoc Health (TDOC), Intel (INTC), Alibaba Group (BABA) and PayPal (PYPL). Fund Details IssuerGlobal X Fund NameGlobal X Genomics & Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:GNOM Inception Date4/5/2019 Fund ManagerChang Kim, James Ong, Nam To, Wayne Xie Webwww.completegenomics.com Phone+1-650-9432800Fund Focus Asset ClassEquity BenchmarkSolactive Genomics Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings52 Fund Statistics Assets Under Management$93.74 million Average Daily Volume$0.00 Discount/Premium-0.08% Administrator, Advisor and Custodian AdministratorGlobal X Management Company LLC AdvisorGlobal X Management Company LLC CustodianBrown Brothers Harriman & Co. DistributorSEI Investments Distribution Co. Transfer AgentBrown Brothers Harriman & Co. TrusteeN/A Lead Market MakerSusquehanna Miscellaneous Outstanding Shares1,999,000Beta1.19 Creation Unit50,000 Creation Fee$500.00 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report Top 10 GNOM HoldingsModerna (NASDAQ:MRNA)Holding Weight: 7.35%Twist Bioscience (NASDAQ:TWST)Holding Weight: 6.43%10x Genomics (NASDAQ:TXG)Holding Weight: 5.38%Guardant Health (NASDAQ:GH)Holding Weight: 5.34%Illumina (NASDAQ:ILMN)Holding Weight: 4.89%Natera (NASDAQ:NTRA)Holding Weight: 4.65%Genscript Biotech CorporationHolding Weight: 3.92%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 3.67%Bio-Techne (NASDAQ:TECH)Holding Weight: 3.66%BioMarin Pharmaceutical (NASDAQ:BMRN)Holding Weight: 3.54%Full Holdings DetailsGNOM Sector ExposureGNOM Industry Exposure This page (NASDAQ:GNOM) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global X Genomics & Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Global X Genomics & Biotechnology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNOM Stock Alerts